3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
22
Terminated
10
Recruiting
6
Active not recruiting
6
Not yet recruiting
2
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
15
Ovarian Neoplasms
9
Recurrence
3
Multiple Myeloma
3
Lymphoma, Large B-Cell, Diffuse
3
Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Unrecognized Condition
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasm Epithelial
1
Muscle Invasive Bladder Cancer
1
Mesothelioma, Malignant
1
Lymphoma, Mantle-Cell
1
Lymphoma
1
Leukemia, Plasma Cell
1
Hodgkin Disease
1
HER2-positive Breast Cancer
1
Genetic Predisposition to Disease
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Advanced Solid Tumors
1
Advanced Breast Cancer
1
Interventions
Paclitaxel
16
Carboplatin
15
Bevacizumab
7
Hyperthermic Intraperitoneal Chemotherapy
5
Cisplatin
4
Taxes
3
Gemcitabine
3
Cytoreduction Surgical Procedures
3
Chemotherapy, Adjuvant
3
oregovomab
2
niraparib
2
fluzoparib
2
Topotecan
2
ST 1481
2
Neoadjuvant Therapy
2
Methods
2
Immunohistochemistry
2
Ifosfamide
2
Gene Expression Profiling
2
Filgrastim
2
Educational Status
2
Early Intervention, Educational
2
Amplified Fragment Length Polymorphism Analysis
2
rucaparib
1
pembrolizumab
1
paclitaxel poliglumex
1
olaparib
1
navicixizumab
1
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Fallopian Tube Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled